Professional Documents
Culture Documents
DESCRIPTION
The National Leprosy Control Program (NLCP) is a multi-agency effort to control Leprosy in the
country with private and public partnership in achieving its goals to lessen the burden of the
disease and its mission to have a leprosy-free country.
VISION
MISSION
To ensure the provision of comprehensive, integrated quality leprosy services at all levels of
healthcare
OBJECTIVES
To further reduce the disease burden and sustain provision of high-quality leprosy
services for all affected communities ensuring that the principle of equity and social
justice are followed
To decrease by 50% the identified hyper endemic cities and municipalities
PROGRAM COMPONENTS
PARTNER INSTITUTIONS
Administrative Order No. 167, s. 1965: Rules and Regulations of Leprosy Control in
the Philippines
Republic Act No. 4073: An Act further liberalizing the treatment of leprosy by
amending and repealing certain sections of the revised Administrative Code
Presidential Decree No. 384 January 30, 1974: Amending Republic Act No. 4073
entitled An Act further liberalizing the treatment of leprosy by amending and
repealing certain sections of the revised Administrative Code
Proclamation No. 467: Declaring the Last Week of February of every year as
Leprosy Week
Administrative Order No. 26 – A, s. 1997: Guidelines on Elimination of Leprosy as
Public Health Problem
Administrative Order No. 5, s. 2000: Guidelines on the integration of leprosy
services in hospitals
Department memorandum No. 79, s. 2004: Recommendations to pursue Leprosy
Elimination Activities in all areas in the country
Department Circular 366-B, s. 2003: First Leprosy Forum of the Philippine
Dermatological Society on November 12, 2003
Department Circular 254, s. 2004: Second Leprosy Forum of the Philippine
Dermatological Society on November 9, 2004
The National Leprosy Control Program in coordination with the Research Institute for
Tropical Medicine (RITM) has started the National Leprosy Baseline Survey this year
(2018) and expected to be completed in 2019. This will help the program in prioritizing
augmentation in areas with high prevalence rate. This will also give a real picture of the
country’s status in maintaining the elimination level of leprosy cases.
Continuous support has been given to all new MB and PB cases through provision of
supportive drugs from the NLCP and Multidrug Therapy (MDT) from World Health
Organization (WHO).
CALENDAR OF ACTIVITIES